Milbhor D’Silva , MD, MPH, FICS brings over 28 years of dedicated experience in Drug Safety and Pharmacovigilance (PV), including 26+ years in full-time leadership roles and the past 2 years as an independent consultant. His career spans tactical execution, strategic oversight, and organizational leadership—building and transforming PV functions across clinical-stage startups, mid-size biopharma, and large pharmaceutical companies in the US, EU, Japan, and Canada.
Milbhor has played pivotal roles in both pre- and post-approval safety operations, with a strong track record of regulatory engagement. He has held safety leadership positions within PhRMA, contributing to FDA guidance documents that shape industry standards for drug safety.
His entry into global pharmacovigilance began at Novartis Pharmaceuticals, where he designed a lifelong safety database for human xenotransplant recipients of transgenic porcine organs. This groundbreaking work led to close collaboration with global regulatory bodies—including FDA-CBER, WHO, CDC, and OECD—to address zoonotic retroviral risks in xenotransplantation.
As a consultant, Milbhor advises clinical-stage companies and consulting entities across diverse therapeutic areas: gene therapy, neuroscience, obesity, targeted oncology, and theranostics. He also brings specialized expertise in cannabinoid-based treatments, including nabiximols for CNS disorders and multiple sclerosis.
Veritux independent consultants are available where you need them – in all major markets and every global region.
